Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML

Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy

NCT00387647 ·Status: COMPLETED ·Phase: PHASE2

Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)

NCT00486265 ·Status: TERMINATED ·Phase: PHASE1

5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

NCT01038635 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

NCT00460460 ·Status: TERMINATED ·Phase: PHASE1

Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients

NCT01489722 ·Status: TERMINATED ·Phase: PHASE1

Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients

NCT01010373 ·Status: SUSPENDED ·Phase: PHASE2

Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.

NCT03218683 ·Status: TERMINATED ·Phase: PHASE1

Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations

NCT02272478 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).

NCT01556477 ·Status: UNKNOWN ·Phase: PHASE2

Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

NCT03614728 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

NCT04358393 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.

NCT02310321 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS

NCT01617226 ·Status: COMPLETED ·Phase: PHASE2

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

NCT06564038 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)

NCT00530699 ·Status: COMPLETED ·Phase: PHASE1

Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes

NCT00923234 ·Status: TERMINATED ·Phase: PHASE1

A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)

NCT02892318 ·Status: COMPLETED ·Phase: PHASE1

Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia

NCT01743859 ·Status: COMPLETED ·Phase: PHASE2

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

NCT03328273 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

NCT01861002 ·Status: COMPLETED ·Phase: PHASE1

Azacytidine for the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS/AML) With High Risk (Chromosome 7 and or Complex) Cytogenetic Abnormalities

NCT00915785 ·Status: COMPLETED ·Phase: PHASE2

Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).

NCT01835587 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia

NCT02680951 ·Status: WITHDRAWN ·Phase: PHASE1

Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)

NCT00926731 ·Status: COMPLETED ·Phase: PHASE1

Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma

NCT00761722 ·Status: COMPLETED ·Phase: PHASE1